Lung Foundation Australia. Overview chronic obstructive pulmonary disease. 2022 [cited 16 February 2022]. Available from: https://lungfoundation.com.au/patients-carers/living-with-a-lung-disease/copd/overview/.

Australian Institute of Health and Welfare. Chronic obstructive pulmonary disease (COPD). [Cited16 February 2022]. Available from: https://www.aihw.gov.au/reports/chronic-respiratory-conditions/copd/contents/copd.

Blanco I, Diego I, Bueno P, Casas-Maldonado F, Miravitlles M. Geographic distribution of COPD prevalence in the world displayed by Geographic Information System maps. Eur Respir J. 2019;54(1):1900610.

Article  PubMed  Google Scholar 

World Health Organization. Chronic obstructive pulmonary disease (COPD)

Diez-Manglano J, Barquero-Romero J, Mena PA, Recio-Iglesias J, Cabrera-Aguilar J, Lopez-Garcia F, et al. Polypharmacy in patients hospitalised for acute exacerbation of COPD. Eur Respir J. 2014;44(3):791–4.

Article  PubMed  Google Scholar 

Boom M, Niesters M, Sarton E, Aarts L, Smith TW, Dahan A. Non-analgesic effects of opioids: opioid-induced respiratory depression. Curr Pharm Des. 2012;18(37):5994–6004.

Article  CAS  PubMed  Google Scholar 

Prosser AE, Dawson JL, Koo K, O’Kane KM, Ward MB, Woodman RJ, et al. Real-world incidence of patient-reported dyspnoea with ticagrelor. Ther Adv Drug Saf. 2018;9(10):577–84.

Article  PubMed  PubMed Central  Google Scholar 

Miller KL, Sawitzke AD, Doane J. Abatacept and serious respiratory infections in patients with previous lung disease. Clin Rheumatol. 2008;27(12):1569–71.

Article  PubMed  Google Scholar 

Australian Medicines H. Australian medicines handbook: AMH. AMH; 2022.

Garcia Rodriguez LA, Wallander MA, Tolosa LB, Johansson S. Chronic obstructive pulmonary disease in UK primary care: incidence and risk factors. COPD. 2009;6(5):369–79.

Article  PubMed  Google Scholar 

Jacobson GA, Yee KC, Ng CH. Elevated plasma glutathione peroxidase concentration in acute severe asthma: comparison with plasma glutathione peroxidase activity, selenium and malondialdehyde. Scand J Clin Lab Investig. 2007;67(4):423–30.

Article  CAS  Google Scholar 

Nadeem A, Chhabra SK, Masood A, Raj HG. Increased oxidative stress and altered levels of antioxidants in asthma. J Allergy Clin Immunol. 2003;111(1):72–8.

Article  CAS  PubMed  Google Scholar 

Vlahos R, Bozinovski S. Glutathione peroxidase-1 as a novel therapeutic target for COPD. Redox Rep. 2013;18(4):142–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rahman I. Pharmacological antioxidant strategies as therapeutic interventions for COPD. Biochim Biophys Acta. 2012;1822(5):714–28.

Article  CAS  PubMed  Google Scholar 

Calzetta L, Rogliani P, Facciolo F, Rinaldi B, Cazzola M, Matera MG. N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. Biomed Pharmacother. 2018;103:1–8.

Article  CAS  PubMed  Google Scholar 

Zinellu E, Zinellu A, Pau MC, Piras B, Fois AG, Mellino S, et al. Glutathione peroxidase in stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Antioxidants (Basel). 2021;10(11):1745.

Article  CAS  PubMed  Google Scholar 

Janetzki JL, Pratt NL, Ward MB, Sykes MJ. Application of an integrative drug safety model for detection of adverse drug events associated with inhibition of glutathione peroxidase 1 in chronic obstructive pulmonary disease. Pharm Res. 2023;40:1553–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lai EC, Pratt N, Hsieh CY, Lin SJ, Pottegard A, Roughead EE, et al. Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies. Eur J Epidemiol. 2017;32(7):567–82.

Article  PubMed  Google Scholar 

Pratt NL, Ilomaki J, Raymond C, Roughead EE. The performance of sequence symmetry analysis as a tool for post-market surveillance of newly marketed medicines: a simulation study. BMC Med Res Methodol. 2014;14(1):66.

Article  PubMed  PubMed Central  Google Scholar 

King CE, Pratt NL, Craig N, Thai L, Wilson M, Nandapalan N, et al. Detecting medicine safety signals using prescription sequence symmetry analysis of a national prescribing data set. Drug Saf. 2020;43(8):787–95.

Article  PubMed  Google Scholar 

Roughead EE, Chan EW, Choi NK, Griffiths J, Jin XM, Lee J, et al. Proton pump inhibitors and risk of Clostridium difficile infection: a multi-country study using sequence symmetry analysis. Expert Opin Drug Saf. 2016;15(12):1589–95.

Article  CAS  PubMed  Google Scholar 

World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomical therapeutic chemical code classification index with defined daily doses.

Australian Government Department of Health. Pharmaceutical benefits scheme. 2022 [cited 7 April 2022]. Available from: https://www.pbs.gov.au/pbs/home.

Toelle BG, Xuan W, Bird TE, Abramson MJ, Atkinson DN, Burton DL, et al. Respiratory symptoms and illness in older Australians: the Burden of Obstructive Lung Disease (BOLD) study. Med J Aust. 2013;198(3):144–8.

Article  PubMed  Google Scholar 

Liu Y, Pleasants RA, Croft JB, Wheaton AG, Heidari K, Malarcher AM, et al. Smoking duration, respiratory symptoms, and COPD in adults aged >/=45 years with a smoking history. Int J Chron Obstr Pulm Dis. 2015;10:1409–16.

Article  CAS  Google Scholar 

Janetzki JL, Sykes MJ, Ward MB, Pratt NL. Proton pump inhibitors may contribute to progression or development of chronic obstructive pulmonary disease—a sequence symmetry analysis approach. J Clin Pharm Ther. 2021;46(6):1687–94.

Article  CAS  PubMed  Google Scholar 

Lung Foundation Australia. Stepwise Management of Stable COPD. 2020.

Preiss AK, Roughead EE, Pratt NL. Sequence symmetry analysis graphic adjustment for prescribing trends. BMC Med Res Methodol. 2019;19(1):143.

Article  PubMed  PubMed Central  Google Scholar 

Baker JG, Wilcox RG. Beta-Blockers, heart disease and COPD: current controversies and uncertainties. Thorax. 2017;72(3):271–6.

Article  PubMed  Google Scholar 

MIMS Australia. MIMS Online. Monthly index of medical specialities. St Leonards, N.S.W.: MIMS Australia; 1996.

Gulea C, Zakeri R, Alderman V, Morgan A, Ross J, Quint JK. Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison. Respir Res. 2021;22(1):64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125(6):2309–21.

Article  CAS  PubMed  Google Scholar 

Dorow P, Thalhofer S, Bethge H, Disselhoff G, Wagner G. Long-term treatment of angina pectoris with bisoprolol or atenolol in patients with chronic obstructive bronchitis: a randomized, double-blind crossover study. J Cardiovasc Pharmacol. 1990;16(Suppl 5):S36-44.

Article  PubMed  Google Scholar 

van Zyl AI, Jennings AA, Bateman ED, Opie LH. Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension. Chest. 1989;95(1):209–13.

Article  PubMed  Google Scholar 

Voiriot G, Philippot Q, Elabbadi A, Elbim C, Chalumeau M, Fartoukh M. Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients. J Clin Med. 2019;8(6):786.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Orhan H, Sahin G. In vitro effects of NSAIDS and paracetamol on oxidative stress-related parameters of human erythrocytes. Exp Toxicol Pathol. 2001;53(2–3):133–40.

Article  CAS  PubMed  Google Scholar 

McKeever TM, Lewis SA, Smit HA, Burney P, Britton JR, Cassano PA. The association of acetaminophen, aspirin, and ibuprofen with respiratory disease and lung function. Am J Respir Crit Care Med. 2005;171(9):966–71.

Article  PubMed  Google Scholar 

Montuschi P, Macagno F, Parente P, Valente S, Lauriola L, Ciappi G, et al. Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD. Thorax. 2005;60(10):827–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Health AIo, Welfare. Chronic obstructive pulmonary disease (COPD), associated comorbidities and risk factors. Canberra: AIHW; 2020.

Therapeutic Guidelines. Therapeutic Guidelines. eTG complete. West Melbourne: Therapeutic Guidelines Ltd.; 2003.

Geraghty P, Baumlin N, Salathe MA, Foronjy RF, D’Armiento JM. Glutathione peroxidase-1 suppresses the unfolded protein response upon cigarette smoke exposure. Mediat Inflamm. 2016;2016:9461289.

Article  Google Scholar 

Sethi S. Infection as a comorbidity of COPD. Eur Respir J. 2010;35(6):1209–15.

Article  CAS  PubMed  Google Scholar 

Dalmarco EM, Budni P, Parisotto EB, Wilhelm Filho D, Frode TS. Antioxidant effects of mycophenolate mofetil in a murine pleurisy model. Transpl Immunol. 2009;22(1–2):12–7.

Article  PubMed  Google Scholar 

Faillie JL. Case-non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74(2):225–32.

Article  PubMed  Google Scholar 

Hersom K, Neary MP, Levaux HP, Klaskala W, Strauss JS. Isotretinoin and antidepressant pharmacotherapy: a prescription sequence symmetry analysis. J Am Acad Dermatol. 2003;49(3):424–32.

Article  PubMed  Google Scholar 

Pharmaceutical Benefits Scheme. Post-market review of chronic obstructive pulmonary disease medi